Atherosclerosis
Volume 186, Issue 1 , Pages 20-28 , May 2006

Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells

Received 17 February 2005 ,Revised 21 June 2005 ,Accepted 23 June 2005.

References 

  1. Brown AJ, Dusso AS, Slatopolsky E. Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant. 2002;17:10–19
  2. Carlberg C, Quack M, Herdick M, Bury Y, Polly P, Toell A. Central role of VDR conformations for understanding selective actions of Vitamin D(3) analogues. Steroids. 2001;66:213–221
  3. Zebrack JS, Anderson JL, Beddhu S, et al. Do associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency?. J Am Coll Cardiol. 2003;42:57–63
  4. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307–1315
  5. Martin KJ, Gonzalez EA. Vitamin D analogs: actions and role in the treatment of secondary hyperparathyroidism. Semin Nephrol. 2004;24:456–459
  6. Nakai S, Shinzato T, Nagura Y, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2001). Ther Apher Dial. 2004;8:3–32
  7. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349:446–456
  8. Shoji T, Shinohara K, Kimoto E, et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy Vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant. 2004;19:179–184
  9. Amann K, Ritz C, Adamczak M, Ritz E. Why is coronary heart disease of uraemic patients so frequent and so devastating?. Nephrol Dial Transplant. 2003;18:631–640
  10. Schwarz U, Buzello M, Ritz E, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant. 2000;15:218–223
  11. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res. 2004;95:560–567
  12. Doherty TM, Fitzpatrick LA, Inoue D, et al. Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev. 2004;25:629–672
  13. Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat Med. 2002;8:1235–1242
  14. Cardus A, Gallego C, Muray S, et al. Differential effect of Vitamin D analogues on the proliferation of vascular smooth muscle cells. Nefrologia. 2003;23:117–121
  15. Maurer U, Jehan F, Englert C, et al. The Wilms’ tumor gene product (WT1) modulates the response to 1,25-dihydroxyvitamin D3 by induction of the Vitamin D receptor. J Biol Chem. 2001;276:3727–3732[Epub 2000 October 24]
  16. Damon SE, Plymate SR, Carroll JM, et al. Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. Endocrinology. 2001;142:21–27
  17. Bentov I, LeRoith D, Werner H. The WT1 Wilms’ tumor suppressor gene: a novel target for insulin-like growth factor-I action. Endocrinology. 2003;144:4276–4279[Epub 2003 July 17]
  18. Laukkanen J, Yla-Herttuala S. Genes involved in atherosclerosis. Exp Nephrol. 2002;10:150–163
  19. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321–328
  20. Koyama T, Shibakura M, Ohsawa M, Kamiyama R, Hirosawa S. Anticoagulant effects of 1alpha, 25-dihydroxyvitamin D3 on human myelogenous leukemia cells and monocytes. Blood. 1998;92:160–167
  21. Ohsawa M, Koyama T, Yamamoto K, Hirosawa S, Kamei S, Kamiyama R. 1alpha,25-dihydroxyvitamin D(3) and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Circulation. 2000;102:2867–2872
  22. Aihara K, Azuma H, Akaike M, et al. Disruption of nuclear Vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem. 2004;279:35798–35802[Epub 2004 June 17]
  23. Nordt TK, Peter K, Ruef J, Kubler W, Bode C. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease. Thromb Haemost. 1999;82:14–18
  24. Warner TD, Mitchell JA, de Nucci G, Vane JR. Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. J Cardiovasc Pharmacol. 1989;13(Suppl. 5):S85–S88[discussion S102]
  25. Zingg HH. Vasopressin and oxytocin receptors. Baillieres Clin Endocrinol Metab. 1996;10:75–96
  26. Wu KK. Inducible cyclooxygenase and nitric oxide synthase. Adv Pharmacol. 1995;33:179–207
  27. Watson KE, Abrolat ML, Malone LL, et al. Active serum Vitamin D levels are inversely correlated with coronary calcification. Circulation. 1997;96:1755–1760
  28. Doherty TM, Tang W, Dascalos S, et al. Ethnic origin and serum levels of 1alpha, 25-dihydroxyvitamin D3 are independent predictors of coronary calcium mass measured by electron-beam computed tomography. Circulation. 1997;96:1477–1481
  29. Jono S, Nishizawa Y, Shioi A, Morii H. 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation. 1998;98:1302–1306
  30. Hirata M, Katsumata K, Endo K, Fukushima N, Ohkawa H, Fukagawa M. In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 Vitamin D3. Nephrol Dial Transplant. 2003;18:1770–1776
  31. Wolisi GO, Moe SM. The role of Vitamin D in vascular calcification in CKD. Semin Dial. 2005;18:307–314
  32. Chen NX, O’Neill KD, Duan D, Moe SM. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int. 2002;62:1724–1731
  33. Mitsuhashi T, Morris RC, Ives HE. 1,25-dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. J Clin Invest. 1991;87:1889–1895

☆ Some of the expression profiling data were presented at the 2005 Keystone Symposium on “The Cellular Biology of Atherosclerosis”.

PII: S0021-9150(05)00446-6

doi: 10.1016/j.atherosclerosis.2005.06.046

Atherosclerosis
Volume 186, Issue 1 , Pages 20-28 , May 2006

Article Tools

* Image Usage & Resolution